AR089014A1 - Antihelminticos de sulfonamida - Google Patents
Antihelminticos de sulfonamidaInfo
- Publication number
- AR089014A1 AR089014A1 ARP120104468A ARP120104468A AR089014A1 AR 089014 A1 AR089014 A1 AR 089014A1 AR P120104468 A ARP120104468 A AR P120104468A AR P120104468 A ARP120104468 A AR P120104468A AR 089014 A1 AR089014 A1 AR 089014A1
- Authority
- AR
- Argentina
- Prior art keywords
- cyano
- nitro
- halogen
- optionally substituted
- alkyl
- Prior art date
Links
- 239000000921 anthelmintic agent Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 22
- 229910052736 halogen Inorganic materials 0.000 abstract 19
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 19
- 125000001424 substituent group Chemical group 0.000 abstract 17
- 125000005843 halogen group Chemical group 0.000 abstract 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 8
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 8
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 2
- 125000004647 alkyl sulfenyl group Chemical group 0.000 abstract 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 2
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 abstract 2
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 abstract 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 208000006968 Helminthiasis Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se describen composiciones que los contienen y su uso para tratar infecciones de helmintos. Reivindicación 1: Un compuesto de la fórmula (1), un N-óxido o sal de este caracterizado porque, Q es fenilo o naftalenilo cada uno opcionalmente sustituido con hasta 5 sustituyentes seleccionados independientemente de R⁴ᵃ; o Q es un anillo heteroaromático de 5 a 6 miembros o un sistema anular bicíclico heteroaromático de 8 a 11 miembros, cada anillo o sistema anular contiene miembros del anillo seleccionados de átomos de carbono y hasta 4 heteroátomos seleccionados independientemente de hasta 2 O, hasta 2 S y hasta 4 N y opcionalmente sustituidos con hasta 5 sustituyentes seleccionados independientemente de R⁴ᵃ en miembros de anillo de átomos de carbono y R⁴ᵇ en miembros de anillo de átomos de nitrógeno; A es N, CH o CR¹; cada R¹ es independientemente halógeno, ciano, nitro, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² o S(O)₂NR¹⁰R¹¹; o alquilo C₁₋₆, alquenilo C₂₋₆ o alquinilo C₂₋₆, cada uno opcionalmente sustituido con sustituyentes seleccionados del grupo que consiste en halógeno, ciano, nitro, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² y S(O)₂NR¹⁰R¹¹; o cicloalquilo C₃₋₇, cicloalquilalquilo C₄₋₈ o cicloalquenilo C₅₋₇, cada uno opcionalmente sustituido con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, ciano, nitro, alquilo C₁₋₄, haloalquilo C₁₋₄, OR⁶ y S(O)ₚR¹²; R² es hidrógeno, ciano, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² o S(O)₂NR¹⁰R¹¹; o alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆ o bencilo, cada uno opcionalmente sustituido con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, ciano, nitro, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² y S(O)₂NR¹⁰R¹¹; o cicloalquilo C₃₋₇, cicloalquilalquilo C₄₋₈ o cicloalquenilo C₅₋₇, cada uno opcionalmente sustituido con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, ciano, nitro, alquilo C₁₋₄, haloalquilo C₁₋₄, OR⁶ y S(O)ₚR¹²; R³ es hidrógeno, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹², S(O)₂NR¹⁰R¹¹ o Si(R¹³)₃; o alquilo C₁₋₆, alquenilo C₂₋₆ o alquinilo C₂₋₆, cada uno opcionalmente sustituido con sustituyentes seleccionados del grupo que consiste en halógeno, ciano, nitro, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² y S(O)₂NR¹⁰R¹¹; o cicloalquilo C₃₋₇, cicloalquilalquilo C₄₋₈ o cicloalquenilo C₅₋₇, cada uno opcionalmente sustituido con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, ciano, nitro, alquilo C₁₋₄, haloalquilo C₁₋₄, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² y S(O)₂NR¹⁰R¹¹; o G; G es un anillo heterocíclico aromático de 5 a 6 miembros, un anillo heterocíclico no aromático de 3 a 7 miembros o un sistema anular bicíclico heterocíclico no aromático de 8 a 11 miembros, cada anillo o sistema anular contiene miembros anulares seleccionados de átomos de carbono y hasta 4 heteroátomos seleccionados independientemente de átomos de hasta 2 O, hasta 2 S y hasta 4 N, y opcionalmente sustituidos con hasta 5 sustituyentes seleccionados independientemente de R⁵ᵃ en miembros de anillo de átomos de carbono y R⁵ᵇ en miembros de anillo de átomos de nitrógeno; cada R⁴ᵃ es independientemente halógeno, ciano, nitro, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² o S(O)₂NR¹⁰R¹¹; o alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cada uno opcionalmente sustituido del grupo que consiste en halógeno, ciano, nitro, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² y S(O)₂NR¹⁰R¹¹; o cicloalquilo C₃₋₇, cicloalquilalquilo C₄₋₈ o cicloalquenilo C₅₋₇, cada uno opcionalmente sustituido con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, ciano, nitro, alquilo C₁₋₄, haloalquilo C₁₋₄, OR⁶ y S(O)ₚR¹²; R⁴ᵇ es ciano, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² o S(O)₂NR¹⁰R¹¹; o alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆ o bencilo, cada uno opcionalmente sustituido con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, ciano, nitro, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² y S(O)₂NR¹⁰R¹¹; o cicloalquilo C₃₋₇, cicloalquilalquilo C₄₋₈ o cicloalquenilo C₅₋₇, cada uno opcionalmente sustituido con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, ciano, nitro, alquilo C₁₋₄, haloalquilo C₁₋₄, OR⁶ y S(O)ₚR¹²; cada R⁵ᵃ es independientemente halógeno, ciano, nitro, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² o S(O)₂NR¹⁰R¹¹; o alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cada uno opcionalmente sustituido del grupo que consiste en halógeno, ciano, nitro, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² y S(O)₂NR¹⁰R¹¹; o cicloalquilo C₃₋₇, cicloalquilalquilo C₄₋₈ o cicloalquenilo C₅₋₇, cada uno opcionalmente sustituido con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, ciano, nitro, alquilo C₁₋₄, haloalquilo C₁₋₄, OR⁶ y S(O)ₚR¹²; cada R⁵ᵇ es ciano, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² o S(O)₂NR¹⁰R¹¹; o alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆ o bencilo, cada uno opcionalmente sustituido con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, ciano, nitro, OR⁶, NR⁷ᵃR⁷ᵇ, C(O)R⁸, C(O)OR⁹, C(O)NR¹⁰R¹¹, S(O)ₚR¹² y S(O)₂NR¹⁰R¹¹; o cicloalquilo C₃₋₇, cicloalquilalquilo C₄₋₈ o cicloalquenilo C₅₋₇, cada uno opcionalmente sustituido con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, ciano, nitro, alquilo C₁₋₄, haloalquilo C₁₋₄, OR⁶ y S(O)ₚR¹²; cada R⁶ es independientemente hidrógeno, alquilcarbonilo C₂₋₆, alcoxicarbonilo C₂₋₆, alquilaminocarbonilo C₂₋₆, dialquilaminocarbonilo C₃₋₈, alquilsulfenilo C₁₋₆, alquilsulfinilo C₁₋₆, alquilsulfonilo C₁₋₆, alquilaminosulfonilo C₂₋₆ o dialquilaminosulfonilo C₃₋₆; o alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆ o bencilo, cada uno opcionalmente sustituido con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, ciano, nitro, alcoxi C₁₋₆, alquilamino C₁₋₆, dialquilamino C₂₋₈, alquilcarbonilo C₂₋₆, alcoxicarbonilo C₂₋₆, alquilaminocarbonilo C₂₋₆, dialquilaminocarbonilo C₃₋₆, alquilsulfenilo C₁₋₆, alquilsulfinilo C₁₋₆, alquilsulfonilo C₁₋₆, alquilaminosulfonilo C₂₋₆ y dialquilaminosulfonilo C₃₋₆ o cicloalquilo C₃₋₇, cicloalquilalquilo C₄₋₈ o cicloalquenilo C₅₋₇, cada uno opcionalmente sustituido con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, ciano, nitro, alquilo C₁₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, alquilsulfenilo C₁₋₄, alquilsulfinilo C₁₋₄ y alquilsulfonilo C₁₋₄; cada R⁷ᵃ es independientemente hidrógeno, alquilcarbonilo C₂₋₆, alcoxicarbonilo C₂₋₆, alquilaminocar
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563926P | 2011-11-28 | 2011-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089014A1 true AR089014A1 (es) | 2014-07-23 |
Family
ID=47179004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104468A AR089014A1 (es) | 2011-11-28 | 2012-11-28 | Antihelminticos de sulfonamida |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20140315857A1 (es) |
| EP (1) | EP2785694A1 (es) |
| JP (1) | JP2015502936A (es) |
| KR (1) | KR20140094026A (es) |
| CN (1) | CN103958476A (es) |
| AR (1) | AR089014A1 (es) |
| AU (1) | AU2012346433A1 (es) |
| BR (1) | BR112014012759A8 (es) |
| CA (1) | CA2855001A1 (es) |
| CL (1) | CL2014001377A1 (es) |
| CO (1) | CO6980661A2 (es) |
| IL (1) | IL232404A0 (es) |
| MA (1) | MA35742B1 (es) |
| MX (1) | MX2014006317A (es) |
| PH (1) | PH12014501181A1 (es) |
| RU (1) | RU2014126367A (es) |
| SG (1) | SG11201402664VA (es) |
| TN (1) | TN2014000166A1 (es) |
| TW (1) | TW201326128A (es) |
| WO (1) | WO2013081783A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014065411A1 (ja) * | 2012-10-26 | 2014-05-01 | 株式会社エス・ディー・エス バイオテック | 農園芸用の有害生物防除剤としてのスルホンアミド誘導体 |
| WO2014099837A1 (en) * | 2012-12-18 | 2014-06-26 | E. I. Du Pont De Nemours And Company | Sulfonamide anthelmintics |
| MX2019005569A (es) * | 2016-11-11 | 2019-09-05 | Bayer Animal Health Gmbh | Nuevos derivados de quinolina. |
| CN110770227B (zh) * | 2017-06-30 | 2024-03-01 | 拜耳动物保健有限责任公司 | 新的氮杂喹啉衍生物 |
| WO2022173727A1 (en) * | 2021-02-09 | 2022-08-18 | Celgene Corporation | Sulfonamides and their use for treatment of helminthic infections and diseases |
| US11905306B2 (en) | 2021-12-21 | 2024-02-20 | Southern Research Institute | Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of SARS virus |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1815604A (en) | 1922-10-31 | 1931-07-21 | Winthrop Chem Co | Organic mercury compound |
| US1679404A (en) | 1926-02-04 | 1928-08-07 | Rockwood Sprinkler Co Massachusetts | Constant-alarm device for alarm valves |
| US1959705A (en) | 1931-08-12 | 1934-05-22 | Standard Steel Car Corp | Car door |
| US5299582A (en) | 1991-09-16 | 1994-04-05 | Little Rapids Corporation | Surgical isolation apparatus |
| US5399582A (en) | 1993-11-01 | 1995-03-21 | Merck & Co., Inc. | Antiparasitic agents |
| US6221894B1 (en) | 1995-03-20 | 2001-04-24 | Merck & Co., Inc. | Nodulisporic acid derivatives |
| US5962499A (en) | 1995-03-20 | 1999-10-05 | Merck & Co., Inc. | Nodulisporic acid derivatives |
| US5595991A (en) | 1995-03-20 | 1997-01-21 | Merck & Co., Inc. | Anthelmintic use of nodulisporic acid and analogs thereof |
| BR9607965A (pt) | 1995-03-20 | 1998-07-14 | Merck & Co Inc | Composto composição farmacêutica e processo para tratar uma doença parasítica em um mamífero |
| US5958888A (en) | 1996-07-02 | 1999-09-28 | Merial, Inc. | Water miscible macrolide solutions |
| US6271255B1 (en) | 1996-07-05 | 2001-08-07 | Biotica Technology Limited | Erythromycins and process for their preparation |
| US5834260A (en) | 1996-08-30 | 1998-11-10 | Merck & Co., Inc. | Antiparasitic agents |
| US6339063B1 (en) | 1997-09-10 | 2002-01-15 | Merck & Co., Inc. | 9a-azalides as veterinary antimicrobial agents |
| JP2003512290A (ja) | 1997-09-10 | 2003-04-02 | メルク エンド カムパニー インコーポレーテッド | 家畜抗菌剤としての８ａ−アザライド |
| AP9801420A0 (en) | 1998-01-02 | 1998-12-31 | Pfizer Prod Inc | Novel macrolides. |
| US6136838A (en) | 1998-03-19 | 2000-10-24 | Merck & Co., Inc. | Sulfurpentafluorophenylpyrazoles for controlling ectoparasitic infestations |
| US6239112B1 (en) | 1998-07-09 | 2001-05-29 | Merial, Inc. | Water miscible macrolide solutions |
| CA2292359C (en) | 1999-01-28 | 2004-09-28 | Pfizer Products Inc. | Novel azalides and methods of making same |
| PT1250343E (pt) | 2000-01-27 | 2003-11-28 | Pfizer Prod Inc | Composicoes de antibioticos de azalida |
| US6399796B2 (en) | 2000-03-17 | 2002-06-04 | Roche Vitamins Inc. | Activation of a Diels-Alder reaction of a sterol 5,7-diene |
| TW200406372A (en) | 2002-03-08 | 2004-05-01 | Schering Plough Ltd | Novel florfenicol-type antibiotics |
| EA008948B1 (ru) * | 2003-09-18 | 2007-10-26 | Басф Акциенгезельшафт | Новые сульфонамиды в качестве средств защиты растений |
| JP4719160B2 (ja) | 2003-12-23 | 2011-07-06 | シェーリング−プラウ・リミテッド | 改善された水溶性を有するフロルフェニコールプロドラッグ |
| US7361689B2 (en) | 2003-12-31 | 2008-04-22 | Schering-Plough Animal Health Corporation | Antibacterial 1-(4-mono- and di-halomethylsulphonylphenyl)-2-acylamino-3-fluoroproponals and preparation thereof |
| CA2551867C (en) | 2003-12-31 | 2010-08-17 | Schering-Plough Ltd. | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives |
| EP1571150A1 (en) | 2004-03-02 | 2005-09-07 | Aventis Pharma Deutschland GmbH | Process for the preparation of tryptase inhibitors |
| CN101065352A (zh) | 2004-09-23 | 2007-10-31 | 先灵-普劳有限公司 | 使用新的三氟甲磺酰苯胺肟醚衍生物控制动物中的寄生虫 |
| US7642391B1 (en) | 2005-03-04 | 2010-01-05 | Iowa State University Research Foundation, Inc. | Palladium-catalyzed coupling of aryl halides with alkynes |
| KR20070112853A (ko) | 2005-03-16 | 2007-11-27 | 바스프 악티엔게젤샤프트 | 절지류 해충 방제를 위한 ｎ-(4-피리딜)메틸설폰아미드의용도 |
| MX2007015729A (es) | 2005-06-09 | 2008-02-21 | Schering Plough Ltd | Control de parasitos en animales con derivados de n-[(feniloxi)fenil]-1,1,1-trifluorometansulfonamida y de n[(fenilsulfanil)fenil]-1,1,1-trifluorometansulfonamida. |
| US20070285554A1 (en) | 2005-10-31 | 2007-12-13 | Dor Givon | Apparatus method and system for imaging |
| EA200801775A1 (ru) * | 2006-02-14 | 2009-02-27 | Басф Се | Пиридин-4-илметиламиды для борьбы с вредителями |
| AU2007224465A1 (en) | 2006-03-15 | 2007-09-20 | Basf Se | Quinoline derivatives and their use as pesticides |
| BRPI0713502A2 (pt) | 2006-06-20 | 2012-03-13 | F. Hoffmann-La Roche Ag | derivados de tetralina de arilsulfonamidil e empregos destes |
| WO2008007211A1 (en) | 2006-07-11 | 2008-01-17 | Pfizer Japan Inc. | Substituted n-bicyclicalkyl bicyclic carboxyamide compounds |
| TW200819428A (en) * | 2006-09-12 | 2008-05-01 | Basf Ag | Quinolinylmethyl compounds |
| AU2007338793B2 (en) | 2006-12-20 | 2012-05-03 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
| WO2008090434A1 (en) | 2007-01-25 | 2008-07-31 | Pfizer Japan Inc. | Substituted n-bicyclicalkyl bicyclic carboxyamide compounds |
| TWI482771B (zh) * | 2009-05-04 | 2015-05-01 | Du Pont | 磺醯胺殺線蟲劑 |
| KR20140038527A (ko) * | 2011-06-20 | 2014-03-28 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 연충 감염을 치료하기 위한 복소환식 화합물 |
-
2012
- 2012-11-07 TW TW101141259A patent/TW201326128A/zh unknown
- 2012-11-07 RU RU2014126367A patent/RU2014126367A/ru unknown
- 2012-11-07 CN CN201280058467.0A patent/CN103958476A/zh active Pending
- 2012-11-07 SG SG11201402664VA patent/SG11201402664VA/en unknown
- 2012-11-07 WO PCT/US2012/063802 patent/WO2013081783A1/en active Application Filing
- 2012-11-07 US US14/358,196 patent/US20140315857A1/en not_active Abandoned
- 2012-11-07 CA CA2855001A patent/CA2855001A1/en not_active Abandoned
- 2012-11-07 KR KR1020147017532A patent/KR20140094026A/ko not_active Application Discontinuation
- 2012-11-07 AU AU2012346433A patent/AU2012346433A1/en not_active Abandoned
- 2012-11-07 EP EP12787321.4A patent/EP2785694A1/en not_active Withdrawn
- 2012-11-07 JP JP2014543484A patent/JP2015502936A/ja active Pending
- 2012-11-07 BR BR112014012759A patent/BR112014012759A8/pt not_active Application Discontinuation
- 2012-11-07 MX MX2014006317A patent/MX2014006317A/es unknown
- 2012-11-28 AR ARP120104468A patent/AR089014A1/es unknown
-
2014
- 2014-04-18 TN TNP2014000166A patent/TN2014000166A1/en unknown
- 2014-05-01 IL IL232404A patent/IL232404A0/en unknown
- 2014-05-26 PH PH12014501181A patent/PH12014501181A1/en unknown
- 2014-05-26 CL CL2014001377A patent/CL2014001377A1/es unknown
- 2014-06-10 CO CO14125212A patent/CO6980661A2/es unknown
- 2014-06-23 MA MA37145A patent/MA35742B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013081783A1 (en) | 2013-06-06 |
| BR112014012759A2 (pt) | 2017-06-13 |
| SG11201402664VA (en) | 2014-06-27 |
| CN103958476A (zh) | 2014-07-30 |
| US20140315857A1 (en) | 2014-10-23 |
| PH12014501181A1 (en) | 2014-09-08 |
| TW201326128A (zh) | 2013-07-01 |
| EP2785694A1 (en) | 2014-10-08 |
| KR20140094026A (ko) | 2014-07-29 |
| AU2012346433A1 (en) | 2014-05-08 |
| CA2855001A1 (en) | 2013-06-06 |
| CL2014001377A1 (es) | 2014-10-17 |
| MX2014006317A (es) | 2014-06-23 |
| BR112014012759A8 (pt) | 2017-06-20 |
| RU2014126367A (ru) | 2016-01-27 |
| CO6980661A2 (es) | 2014-06-27 |
| IL232404A0 (en) | 2014-06-30 |
| JP2015502936A (ja) | 2015-01-29 |
| TN2014000166A1 (en) | 2015-09-30 |
| MA35742B1 (fr) | 2014-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089014A1 (es) | Antihelminticos de sulfonamida | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| PE20190653A1 (es) | Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR100059A1 (es) | Compuestos útiles como inmunomoduladores | |
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| SI2751083T1 (en) | Quinolone compound | |
| BR112015005817A2 (pt) | compostos de bis(fluoroalquil)-1,4-benzodiazepinona como inibidores de notch | |
| AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| AR098171A1 (es) | Piridinilimidazolonas como herbicidas | |
| AR087549A1 (es) | Derivados de 5-fluor-4-imino-3-(sustituido)-3,4-dihidropirimidin-2(1h)ona | |
| AR090670A1 (es) | Compuestos herbicidas | |
| PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| AR093795A1 (es) | Oxidos de piridinio, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades respiratorias | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR090376A1 (es) | Compuestos herbicidas | |
| AR114240A1 (es) | Antranilamidas, su uso como insecticida y procesos para su preparación | |
| AR087868A1 (es) | Compuestos de triazolopiridina como moduladores de la tirosina quinasa c-met | |
| AR111251A1 (es) | Herbicidas de piridazinona | |
| AR093798A1 (es) | Compuestos | |
| AR090546A1 (es) | Compuestos herbicidas | |
| EA201591904A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |